Logo.png
Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference
22. März 2022 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in the 2022 Virtual Growth Conference, presented by Maxim Group...
Logo.png
Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07. September 2021 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company, announces that management will...
Logo.png
Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants
29. Juli 2021 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs...
Logo.png
Cocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants
14. Juni 2021 08:30 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., June 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Logo.png
Cocrystal Pharma’s Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online
09. Juni 2021 14:30 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Logo.png
Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox
28. Mai 2021 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., May 28, 2021 (GLOBE NEWSWIRE) -- With great sadness, Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”) announces that Gary Wilcox, Ph.D., Chairman, CEO and...
Logo.png
Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
17. Mai 2021 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., May 17, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Logo.png
Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock
04. Mai 2021 18:41 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., May 04, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Logo.png
Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs
03. Mai 2021 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., May 03, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Logo.png
Cocrystal Pharma Reports 2020 Financial Results, Provides Business Update Including Antiviral Program Milestones
17. März 2021 08:30 ET | Cocrystal Pharma, Inc.
Outlines 2021 product pipeline milestones for COVID-19, influenza A and norovirus antiviral programs Ends 2020 with cash exceeding $33 million and a clean capital structure BOTHELL, Wash., March...